ABSTRACT: Background. Cetuximab was approved for use in chemoradiation therapy (CRT) for locally advanced head and neck squamous cell carcinoma (HNSCC) in 2006. Methods. Among 3705 patients with locally advanced HNSCC identified in the linked Surveillance Epidemiology and End Results (SEER) Medicare database, we assessed treatment trends, including surgery, radiation therapy (RT), CRT, and specific agents used in CRT. We examined the influence of demographic and clinical characteristics on the likelihood of receiving CRT before and after 2006.
INTRODUCTION
Elderly patients are disproportionately affected by head and neck squamous cell carcinoma (HNSCC), with >40% of incident cases and more than half of deaths from the disease occurring in patients aged 65 years and older. 1, 2 The majority of patients present with either larger primary tumors or have regional lymph node involvement. The curative management of locally or regionally advanced HNSCC includes complete resection of the tumor and regional lymph nodes typically followed by radiation. Definitive radiation therapy (RT) commonly incorporating chemotherapy is an organ-preserving alternative to surgical resection, and can also be used in patients with unresectable tumors. 3 In patients who are not treated surgically, the addition of chemotherapy to RT (chemoradiation therapy [CRT] ) has been shown to improve overall survival by 4.5% at 5 years when compared to RT alone. [4] [5] [6] The improved tumor control associated with CRT may come at the cost of more acute and long-term treatment-related toxicities, which can be severe, particularly among older patients and those with comorbid medical conditions or poor performance status. [7] [8] [9] This potential for added toxicity is especially relevant since a meta-analysis of more than 17,000 clinical trial participants showed no clear overall survival benefit of adding chemotherapy to RT in patients older than 70 years of age. 10 The most recent addition to the drug armamentarium in HNSCC is cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), it was approved in 2006 for concurrent use with RT in locally or regionally advanced disease. In the registration trial, adding cetuximab to radiation improved locoregional control from 34% to 47% and improved 5-year overall survival by 5% when compared to RT alone. 11 Unlike more traditional agents, when combined with RT, there was no increase in common acute radiation-associated toxicity or a decline in patient-reported quality of life with the addition of cetuximab. 12 Older patients -over the age of 65 in a post hoc subset analysis -did not demonstrate an overall survival benefit from the addition of cetuximab to RT.
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Our objectives were to assess the impact of the approval of cetuximab on the use of CRT in older patients with advanced nonmetastatic HNSCC and to characterize trends in the use of specific chemotherapeutic agents among patients receiving CRT.
MATERIALS AND METHODS

Data
The primary data source was the Surveillance Epidemiology and End Results (SEER) cancer registry program records linked with Medicare claims. Sponsored by the National Cancer Institute (NCI), SEER is a consortium of population-based cancer registries covering approximately 28% of the U.S. population. For all incident cancers in their coverage areas, the SEER registries collect information regarding site and extent of disease, the first course of cancer-directed therapy, and sociodemographic characteristics, with active follow-up for date and cause of death. Medicare is the primary health insurer for 97% of the U.S. population age 65 years and older and covers inpatient hospital care (Part A), and outpatient care and physician services (Part B). The SEER-Medicare files were used in accordance with a data-use agreement between the NCI and the Centers for Medicare and Medicaid Services. This study was approved by the Institutional Review Board at Memorial Sloan Kettering Cancer Center.
Study cohort
We identified all Medicare beneficiaries aged 66 years or older with a pathologically confirmed primary diagnosis of advanced nonmetastatic HNSCC (American Joint Committee on Cancer stages III, IVa, or IVb) arising in the oropharynx, hypopharynx, or larynx between January 1, 2001, and December 31, 2009. We included beneficiaries aged 66 or older to ensure a full year of Medicare claims before diagnosis for identifying comorbid conditions. We excluded patients enrolled in a Medicare managed care plan (health maintenance organization) and those who did not have continuous Medicare coverage from 1 year before to 6 months after diagnosis in order to capture all relevant treatments. Patients who were diagnosed only at the time of death, who had a history of another malignancy, or who had metastatic disease at diagnosis were also excluded. Patients who did not have a claim for either RT or surgery within 6 months of diagnosis were considered to not have received definitive therapy and were excluded.
Outcomes
The primary endpoint was type of first-line therapy, classified as surgery, CRT, or RT alone. If a patient had a claim for head and neck cancer-directed surgery before any claim for RT, treatment was classified as surgery. In patients with any claim for RT and no prior cancerdirected surgery within 6 months of diagnosis, treatment was classified as CRT if there was at least one claim for chemotherapy, or as RT alone if there were no claims for chemotherapy. Using Common Procedural Terminology J codes, patients who received CRT were also assigned to 1 of 4 mutually exclusive treatment groups according to the specific chemotherapy agents they received. The grouping system was hierarchical in that any patient receiving cetuximab, either alone or in combination with any other chemotherapeutic agent, was classified as having had cetuximab. The remaining categories were cisplatin therapy alone, any other platinum-containing regimen, including carboplatin, or a regimen with no cetuximab or platinum agent.
Covariates
Demographic and disease characteristics included age, sex, race, marital status, urban or rural residence, geographic region, year of diagnosis, primary site of disease, tumor stage, and lymph node involvement. In the absence of individual-level information about socioeconomic status, we used median income in the census tract of residence at the time of diagnosis. Comorbidity was estimated using a modification of the Charlson index based on inpatient, outpatient, and physician claims in the year before diagnosis.
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Statistical analysis
We used descriptive statistics to compare patients treated with CRT to those treated with surgery or RT alone. We assessed the trends in the treatment of locally advanced HNSCC. To examine the impact of cetuximab approval in 2006 on the use of CRT, we divided the study period into pre-cetuximab approval (2001 thru 2005) and post-cetuximab approval (2006 thru 2009). We used the Cochran-Armitage trend test to evaluate changes over time in the proportion of all patients receiving CRT versus other (surgery or RT). We then used a multivariable logistic regression to evaluate the impact of age, comorbidity, and clinical stage on the likelihood of receiving CRT in each of these time periods. In patients treated with CRT for whom information on specific chemotherapy was available, we evaluated trends in chemotherapy selection over the entire study period, including the use of cetuximab since 2006. All analyses were performed in SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Cohort characteristics
We identified 3705 patients treated for advanced nonmetastatic HNSCC (Table 1 ). The median age was 73 years (range, 66-100 years) and 19% were 80 years or older. The majority of patients were men (75%), white (83%), married (54%), and had a Charlson comorbidity score of 0 (56%). Almost half (47%) of the group had primary tumors arising in the larynx. More than a quarter (26%) had T4 tumors and 64% had lymph node involvement. Overall, 1143 patients (31%) had surgery, 1683 (45%) received CRT, and 879 (24%) were treated with RT alone.
Patients who received CRT were similar with patients treated with surgery in terms of age and comorbidity compared with patients treated with RT only who tended to be older (p < .0001) and have more comorbid illnesses (p < .0001). The oropharynx and hypopharynx were more likely to be treated with CRT, whereas laryngeal tumors were more likely to be treated with RT alone or surgery (p < .0001). Although there was no significant difference in treatment by sex, race, or income quartile, those living in urban regions were slightly more likely to receive CRT than rural areas (p 5 .016).
Trends in treatment
As presented in Figure 1 , the use of surgery declined over the study period from 38% of patients diagnosed in Table 2) . Although patients aged 70 to 79 were slightly more likely to receive CRT than younger patients, patients over the age of 80 were as likely as patients younger than 70 years to receive CRT after 2006. Patients with laryngeal primary tumors were less likely to receive CRT than patients with pharyngeal primary tumors, and patients with T1 tumors were less likely to receive CRT before and after 2006 than patients with larger tumors. Information about specific chemotherapeutic agents was available for 1503 of the 1683 patients (89%) treated with CRT. Cetuximab was the most commonly used concurrent agent after 2006 and used in 32%, 47%, and 74% of patients aged 66 to 69, 70 to 79, and 80 or older, respectively. Cisplatin alone was used for 24% of patients receiving CRT in 2001. The percentage of patients receiving cisplatin alone increased to a third of patients receiving CRT in 2004 but then declined with the availability of cetuximab (see Figure 2) . Although other platinum regimens constituted 63% of concurrent chemotherapy before 2006, these regimens were only used in 27% of patients diagnosed after cetuximab approval. When looking at chemotherapy use during CRT by age, other platinum regimens were used in 63% of patients under the age of 80 and 66% of patients aged 80 and over treated before 2006. In 2006 and after, the use declined to 31% of patients aged 66 to 69 years, 27% of patients aged 70 to 79 years, and 19% of patients aged 80 or older. In patients with a Charlson comorbidity score <2 treated with CRT after 2006, the choice of chemotherapy was cetuximab (44%), cisplatin alone (27%), another platinum regimen (27%), and other (1%). In patients with a Charlson comorbidity score 2, the choice of chemotherapy was cetuximab (54%), other platinum (25%), cisplatin alone (13%), and other (5%). The use of noncetuximab, non-platinum regimens was modest throughout the study period.
DISCUSSION
We observed an increase in the use of CRT and a decline in the use of surgery and RT alone in a population-based cohort of older patients diagnosed with locally advanced HNSCC. For the healthiest patients who are generally considered good surgical candidates, CRT offers the potential for organ preservation with no detriment to overall survival. 4 For patients with unresectable disease, CRT has been shown to improve survival compared to RT alone. 6, 15, 16 Although the use of CRT seemed to be increasing before 2006, our analysis suggests that the approval of cetuximab may have further encouraged the use of CRT in an older and sicker cohort.
Although there is improvement in local tumor control, there is limited evidence on the survival benefit of adding chemotherapy to RT in elderly patients with locally or regionally advanced HNSCC. The lack of an obvious survival benefit in this subset of patients is likely due to, at least in part, higher rates of death because of non-HNSCC causes, diluting survival benefits. 17, 18 Older patients are also more likely to have both comorbid conditions and age-related pharmacokinetic and pharmacodynamic changes that can increase the risk of treatmentrelated toxicities associated with incomplete treatment delivery and death. [19] [20] [21] [22] [23] In one study of patients over 65 receiving CRT, 65% had either an emergency department visit or a hospitalization for an acute treatment-related toxicity within 6 months of starting treatment. 24 Similarly, single institution studies have found that although CRT can be safely administered in older patients without an increased risk of death during treatment, these patients face a greater likelihood of experiencing an acute toxicity compared with their younger counterparts. 9, 25 Further, in patients treated with CRT on 3 different Radiation Therapy Oncology Group studies, older age was associated with an increased risk of experiencing late swallowing dysfunction. 26 Yet, age is not a proxy for functional status and may not adequately determine which patients are most likely to tolerate and complete a full course of CRT. In our study, the oldest and sickest patients were less likely to receive CRT before 2006, but not after. We found a slightly higher likelihood of CRT in patients 70 to 79 years old (p 5 .02) compared with patients aged 66 to 69, which may represent an evolving change in practice, such as increased use of more advanced surgical techniques, but further follow-up will be needed to clarify. Although the availability of cetuximab is one possible cause for the increased use of CRT, the trends could also reflect increased experience and comfort in administering CRT and supporting patients through the potentially toxic treatment. [27] [28] [29] There are currently multiple single agents and doublet chemotherapy regimens for concurrent use with RT in locally or regionally advanced HNSCC that have not been compared prospectively. 3 Often, the choice of an appropriate regimen is based on a patient's clinical profile (functional status and comorbid illness) and the toxicity expected from specific chemotherapeutic agents. In our analysis, cetuximab was the most commonly used concurrent agent in elderly patients receiving CRT after it received U.S. Food and Drug Administration approval in 2006. Although cetuximab integrated with definitive RT improved survival compared to RT alone in a phase III trial, cetuximab with RT has not yet been prospectively compared to other concurrent CRT options. In selected retrospective, single-institution studies, the combination of cetuximab and RT seems less efficacious than cisplatin and radiation. [30] [31] [32] Further, data from prospective trials in the setting of metastatic HNSCC setting suggest that not all tumors respond the same to EGFR inhibitors. Specifically, recently published and presented data suggests that patients with human papillomavirus (HPV)-related tumors have a lower response rate to EGFR inhibition compared with patients with tumors that are negative for HPV. [33] [34] [35] Yet, Rosenthal et al 36 recently presented follow-up correlative data from the original phase III trial of RT alone versus cetuximab plus RT, and those with p161 disease, a surrogate for HPV-related disease, had statistically significant longer locoregional control when treated with cetuximab and RT compared to RT alone. However, the control arm here was RT alone and not an alternative radiation sensitizer. The results of Radiation Therapy Oncology Group 1016, a randomized trial of cetuximab versus cisplatin concurrent with radiation in locally or regionally advanced HPV-related head and neck cancer, are eagerly awaited in this regard. Single-agent cisplatin remains the most studied and the first-line standard agent recommended for radiation-sensitization for locally or regionally advanced HNSCC. However, cisplatin is associated with potential significant toxicity, such as renal dysfunction and hearing loss, and there is a need for less toxic alternatives. 37, 38 These alternatives, however, must yield improved outcomes to justify any added toxicities and financial costs.
The use of other platinum-based regimens in CRT declined substantially after 2006. We observed that before 2006, almost two thirds of patients in this population receiving CRT were treated with other platinum-based regimens, and this proportion declined to less than a third of patients after 2006 when cetuximab became available. The rapid uptake of cetuximab use in CRT in elderly patients with locally advanced HNSCC likely reflects the presumed gentler side effect profile for the targeted agent compared with standard chemotherapy regimens, especially in patients who may be considered poor candidates for cisplatin therapy. However, retrospective studies evaluating cetuximab in clinical practice report that the addition of cetuximab to RT may be associated with more toxicity than reported in the registration trial. 39, 40 Specifically, patients can experience oral mucositis, skin dermatitis, weight loss, and prolonged feeding tube dependence with the combination.
All of the currently recommended chemotherapy agents for locally advanced head and neck cancer, with the exception of cetuximab, are available in generic versions, and many are used off-label when administered with RT. 41 Despite having greater experience with generic radiation sensitizers, our study shows that, in older patients, oncologists are electing to use cetuximab, which is associated with significantly greater drug cost than other accepted regimens. As there are unlikely to be prospective randomized trials comparing alternative chemotherapy regimens to one another, methods of assessing the comparative effectiveness of these options are greatly needed. Several limitations of our analysis should be noted. Although we could identify receipt of chemotherapy and in many case the specific agents used, Medicare claims lack the detailed clinical information that would describe chemotherapy and radiation dosages and schedule of administration. [42] [43] [44] Also, in the absence of medical records, we could not determine whether patients received induction chemotherapy in addition to concurrent CRT. We are unable to distinguish between different radiation delivery, such as hyperfractionation or accelerated fractionation. Finally, although we were able to control for important patient and disease characteristics, there may have been residual confounding by unmeasured factors, such as pretreatment functional status, and patient and physician preferences.
CONCLUSIONS
Chemoradiation is increasingly used in patients with locally or regionally advanced HNSCC. Since 2006, cetuximab has replaced platinum-containing regimens to become the most commonly used radiation-sensitizing agent, despite a lack of evidence that cetuximab is associated with superior oncologic outcomes in this population compared to other available agents. In addition, the availability of cetuximab, generally seen as a less toxic alternative to standard chemotherapy, may have also contributed to the use of CRT in older and sicker patients who might have previously been treated with radiation alone.
